Flagship research
One tumour, three data types, one explainable recommendation.
In routine practice, DNA sequencing results, H&E pathology slides and RNA expression are reviewed in separate silos. Our platform fuses all three into a unified representation and produces a multidisciplinary team ready report per patient, with Shapley attributions and causal graphs showing why.
Validation use case: treatment recommendation in non small cell lung cancer. Training uses public, ethically approved cohorts (TCGA-LUAD, TCGA-LUSC, TCIA whole slide images), so Phase 1 needs no proprietary patient data.
NICE NG122Comprehensive NGS now recommended for all NSCLC subtypes (Feb 2026)
NOLCP v4.0Designed around the 14 day molecular result target and Day 21 MDT
Innovate UKSubmitted to the Frontier AI Discovery competition, June 2026